PLoS ONE (Jan 2013)

MGMT Leu84Phe polymorphism contributes to cancer susceptibility: evidence from 44 case-control studies.

  • Jun Liu,
  • Renxia Zhang,
  • Fei Chen,
  • Cuicui Yu,
  • Yan Sun,
  • Chuanliang Jia,
  • Lijing Zhang,
  • Taufiq Salahuddin,
  • Xiaodong Li,
  • Juntian Lang,
  • Xicheng Song

DOI
https://doi.org/10.1371/journal.pone.0075367
Journal volume & issue
Vol. 8, no. 9
p. e75367

Abstract

Read online

BACKGROUND: O(6)-methylguanine-DNA methyltransferase is one of the few proteins to directly remove alkylating agents in the human DNA direct reversal repair pathway. A large number of case-control studies have been conducted to explore the association between MGMT Leu84Phe polymorphism and cancer risk. However, the results were not consistent. METHODS: We carried out a meta-analysis of 44 case-control studies to clarify the association between the Leu84Phe polymorphism and cancer risk. RESULTS: Overall, significant association of the T allele with cancer susceptibility was verified with meta-analysis under a recessive genetic model (P<0.001, OR=1.30, 95%CI 1.24-1.50) and TT versus CC comparison (P=0.001, OR=1.29, 95% CI 1.12-1.50). In subgroup analysis, a significant increased risk was found for lung cancer (TT versus CC, P=0.027, OR=1.67, 95% CI 1.06-2.63; recessive genetic model, P=0.32, OR=1.64, 95% CI 1.04-2.58), whereas risk of colorectal cancer was significantly low under a dominant genetic model (P=0.019, OR=0.84, 95% CI 0.72-0.97). Additionally, a significant association between TT genetic model and total cancer risk was found in the Caucasian population (TT versus CC, P=0.014, OR=1.29, 95% CI 1.05-1.59; recessive genetic model, P=0.009, OR=1.31, 95% CI 1.07-1.61), but not in the Asian population. An increased risk for lung cancer was also verified in the Caucasian population (TT versus CC, P=0.035, OR=1.62, 95% CI 1.04-2.53; recessive genetic model, P=0.048, OR=1.57, 95% CI 1.01-2.45). CONCLUSIONS: These results suggest that MGMT Leu84Phe polymorphism might contribute to the susceptibility of certain cancers.